-
Innovation Ranking
NewInnovation Ranking – Synaptics Inc
Synaptics Inc (Synaptics) is a developer and supplier of custom-designed semiconductor solutions. The company's product portfolio includes fingerprint biometric sensors, touch controller ICs, display drivers ICs, integrated touch and display ICs, touchpad modules, multimedia processors, and imaging among others. Synaptics offers products under brand names such as ClearPad, ClearView, TouchView, TouchPad, ConnectSmart and SecurePad. The company’s solutions find application in smartphones, tablets, PC notebooks, laptops, automotive, headset and hearable, PC accessories, smart home, docking stations and other applications. It operates...
-
Product Insights
Synaptic Vesicle Glycoprotein 2A – Drugs In Development, 2023
Global Markets Direct’s Synaptic Vesicle Glycoprotein 2A provides in depth analysis on Synaptic Vesicle Glycoprotein 2A targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Synaptic Vesicle Glycoprotein...
-
Product Insights
Synaptic Vesicular Amine Transporter – Drugs In Development, 2023
Global Markets Direct’s Synaptic Vesicular Amine Transporter provides in depth analysis on Synaptic Vesicular Amine Transporter targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Synaptic Vesicular Amine...
-
Company Insights
Innovation and Patenting activity of Synaptics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Synaptics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Thematic Analysis
NewComponent Makers Sector Scorecard, Q1 2024 Update – Thematic Intelligence
The component makers sector continues to struggle in the face of some significant challenges. Demand is anemic in two major areas for components: smartphones and electric vehicles (EVs). Both areas require customer investment that is not forthcoming in the face of a credit crunch caused by interest rate rises. Marginal upgrades for mobile phones and EVs that are too expensive for most means limited demand. There is light at the end of the tunnel in the industrial sector, where demand...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levetiracetam ER in Psychosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levetiracetam ER in Psychosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levetiracetam ER in Psychosis Drug Details: Levetiracetam ER (AGB-101) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-552 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-552 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-552 in Alzheimer's Disease Drug Details: ABBV-552 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levetiracetam ER in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levetiracetam ER in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levetiracetam ER in Mild Cognitive Impairment Drug Details: Levetiracetam ER...
-
Analyst Opinions
Advanced Biometrics – Emerging Trends and Technologies in Authentication
Advanced Biometrics Trend Analysis Report Overview Biometrics is the practice of using unique physical or behavioral traits for identification and authentication purposes. Its usage has been increasing day by day. Fingerprint recognition, voice recognition, facial recognition, palm recognition, iris recognition, and behavioral biometrics are some of its key modalities. For instance, iris recognition is often used in high-security applications such as border control and access to secure facilities. The "Advanced Biometrics - Emerging Trends and Technologies in Authentication" report offers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – alpha-dihydrotetrabenazine in Tardive Dyskinesia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - alpha-dihydrotetrabenazine in Tardive Dyskinesia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. alpha-dihydrotetrabenazine in Tardive Dyskinesia Drug Details: Alpha-dihydrotetrabenazine is under development for...